Abstract:The US Preventive Services Task Force (USPSTF) last released recommendations on breast cancer screening in 2016, when they recommended that most women be screened every 2 years starting at age 50 years. In their 2024 recommendations, 1 -3 the USPSTF now recommends initiating screening mammography for all women at age 40 years and screening every 2 years until age 74 years (B recommendation). Similar to the 2016 recommendations, in their updated recommendations, 1 -3 the USPSTF concludes that evidence is insufficient to assess the balance of benefits and harms of screening mammography in women aged 75 years and older (I statement) and that evidence is insufficient to assess the role of supplemental screening for women with dense breasts (I statement). Beyond the change in the recommended age to initiate screening, the new recommendations differ from prior recommendations in 2 critical and related ways: a deliberate focus on health equity and greater reliance on evidence from studies other than randomized clinical trials (RCTs). The 2024 USPSTF recommendations 1 -3 adopt a deliberate focus on health equity, aligning with the USPSTF's effort to incorporate heath equity, race, and antiracism into their recommendations. 4 The 2024 recommendations 1 -3 explicitly strive to address the persistent inequity in breast cancer mortality experienced by Black women in the US, who—despite having lower lifetime breast cancer incidence—are 40% more likely to die of the disease. 5 The reasons for this disparity are thought to be multifactorial and complex but rooted in systemic racism. Black women are more likely than White women to have mammograms of lower quality (despite comparable screening rates), experience longer delays to definitive diagnosis and treatment, and receive less guideline-concordant care. 6 Black women have higher breast cancer incidence in their 30s and 40s than White women and are more likely to have aggressive tumor subtypes, such as triple-negative cancers, perhaps related to the effects of environmental exposures and systemic racism. 5 Whether and how inequitable breast cancer outcomes should inform breast cancer screening practices is uncertain. Notably, RCTs of mammography screening, and even large observational studies, have included few women of color and thus do not shed light on racial and ethnic differences in the benefits and harms of screening. To inform its current recommendations, 1 -3 the USPSTF commissioned a new modeling study assessing the benefits and harms of mammography screening in the average-risk population of US women overall and for Black women specifically. Model inputs included real-world data on treatment, including inferior treatment received by Black women, and higher breast cancer mortality rates among Black women. Across all women, the models estimated that screening every 2 years between ages 50 and 74 years would avert an estimated 6.7 breast cancer deaths per 1000 people screened, while biennial screening starting at age 40 years would avert an additional 1.3 breast cancer deaths. Among Black women, screening every 2 years between ages 50 and 74 would avert an estimated 9.2 breast cancer deaths per 1000 persons screened, while biennial screening starting at age 40 years would avert an additional 1.8 breast cancer deaths. However, screening every 2 years starting at age 40 years also would lead to more false positive tests (1376 false positives per 1000 screened in the general population, and 1253 false positives per 1000 screened in Black women, over a lifetime) and overdiagnosed cancers (ie, cancers that would never become clinically evident in a woman's lifetime in the absence of screening; 14 cancers per 1000 women screened in the general population, and 18 cancers per 1000 women screened among Black women). 1 ,3 Overall, the models suggest that compared with the general population, Black women would derive more benefit from screening, including from starting screening in their 40s, although the additional benefit of screening starting at age 40 years vs age 50 years was small in both groups. Modeling studies can shed light on questions for which RCT data are not available, and the use of modelling to examine the effects of systemic racism and inform strategies to mitigate these effects is intriguing. 7 However, modeling studies also have important limitations, including their reliance on inputs and assumptions that may or may not be transparent or universally agreed on. For example, the USPSTF model identified a breast cancer mortality reduction from mammography of 30% for screening women aged 40 to 74 years, which is substantially higher than reductions from mammography observed in RCTs (8% for women in their 40s and 14% for women in their 50s).<s -Abstract Truncated-

On Breast Cancer Screening in Older Women

Updates in Breast Cancer Screening and Diagnosis

Breast cancer screening: a 35-year perspective

Screening for Breast Cancer: A Comparative Review of Guidelines

NIH Consensus Statement on Breast Cancer Screening for Women in Their 40s: How Will It Affect Patient Care?

Collaborative Modeling to Compare Different Breast Cancer Screening Strategies

Beyond Mammography: New Frontiers in Breast Cancer Screening

More than a Half Century of Misinformation About Breast Cancer Screening

The Cost-Effectiveness of Screening Mammography beyond Age 65 Years

New Recommendations for Breast Cancer Screening—In Pursuit of Health Equity

Abstract A135: Social disparities in breast cancer screening: Up-to-date screening versus overscreening

Diminishing Mortality Benefit of Cancer Screening with Improvements in Treatment

Breast Cancer Screening for Women at Average Risk

Can Screening Older Patients for Cancer Save Lives?

US expert panel says breast cancer screening should begin at 40

Regular Mammography Use Is Associated with Elimination of Age-Related Disparities in Size and Stage of Breast Cancer at Diagnosis

Screening and Selection: The Case of Mammograms

Screening Beyond the Evidence: Patterns of Age and Comorbidity for Breast, Cervical, and Colorectal Cancer Screening

Breast Cancer Screening Interval: Effect on Rate of Late-Stage Disease at Diagnosis and Overall Survival

American Cancer Society Guidelines for Breast Cancer Screening: Update 2003

ACR Appropriateness Criteria® Female Breast Cancer Screening: 2023 Update